Why Researchers Tested a Higher Dose of Semaglutide
Adults with obesity often take weekly injections of the drug Semaglutide (known by brand names such as Ozempic and Wegovy) because it helps with weight loss. However, some people don’t reach their weight-loss goals with the usual dose of 2.4 mg weekly. A new study tested whether a higher dose – 7.2 mg once a week—could help even more people with obesity lose weight.
What Did the Research Discover?
This was a randomized controlled trial (which means people are assigned to semaglutide by chance). Adults with obesity (BMI ≥ 30 kg/m²) were assigned to receive either weekly semaglutide at 7.2 mg or a placebo (no active drug).
The aim was to test the efficacy and safety of 7.2 mg semaglutide in people with obesity who had not achieved full benefit on the lower dose.
Results: Participants receiving the higher dose showed substantially greater weight loss compared to placebo. The safety profile was consistent with known effects of semaglutide, with manageable side effects.
In simpler terms, taking a higher dose of semaglutide helped people lose more body weight and improved outcomes better than not taking the drug, under supervised research conditions.
How Can I Apply This Information?
This study represents research, not yet a change in standard treatment, but it offers useful insight for patients and doctors. If a person has obesity and has already tried the approved 2.4 mg dose of semaglutide without reaching their goals, discussing a higher dose trial or tailored treatment plan with their doctor may be an option. The results show promise that higher doses could lead to greater weight loss, but safety, cost, and individual health must be considered.
Before acting, one should ask a healthcare provider:
- Is the higher dose approved or available in my country?
- What side effects might increase at a higher dose, and how will they be managed?
- How does this treatment fit with my other health conditions or medications?
Until larger studies and official approvals happen for the higher dose, this study only shows there may be a reason to tailor dosing in the future. This finding is not a green-light for everyone to jump to a higher dose.
Source:
Wilding JG, Batterham RL, Davies M, et al. Once-weekly subcutaneous semaglutide 7.2 mg in adults with obesity: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2025 Apr;13(4):293-306. doi:10.1016/S2213-8587(25)00226-8. Accessed by: https://www.sciencedirect.com/science/article/abs/pii/S2213858725002268
